UNSPSC 51283920: Sulfamethoxypyridazine

This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H12N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T034E4NS2Z, chemically known as sulfanilamide, n(sup 1)-(6-methoxy-3-pyridazinyl)- but generally known as sulfamethoxypyridazine, which bears US NIH Compound Identifier 5330. European Medicines Agency schedules Sulfamethoxypyridazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10712MIG.

UNSPSC 51283920 Sulfamethoxypyridazine, a Commodity code, shows limited recent state and local procurement activity directly aligned with the code's nominal scope. The recent opportunities tagged to this code predominantly solicit naloxone, medical and first aid supplies, and generic multi-source pharmaceuticals through cooperative purchasing vehicles and direct procurement — none of which are sulfamethoxypyridazine specifically. State and local issuing bodies acquiring products under this code include county health departments, state health and human services commissions, municipalities, and cooperative purchasing alliances serving multiple jurisdictions. When pharmaceutical procurement does occur under adjacent codes, it typically flows through established wholesaler networks (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with strict compliance requirements around cGMP certification, Drug Supply Chain Security Act adherence, NDC coding, and expiration-date specifications. Issuing bodies imposing sheltered-market set-asides favor small local business enterprises (SLBEs) with bid discounts up to 5 percent, and all vendors must carry comprehensive insurance including professional liability coverage.

Geographic activity in recent postings spans Florida (Seminole County), Texas (Health and Human Services Commission), Minnesota (MMCAP cooperative serving Minnesota and Oregon), and the broader multistate cooperative footprint. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries; the City of Tampa's Bid 26-P-00145 (posted March 25, 2026; due March 13, 2026) for medical and first aid supplies with an estimated contract value of $700,000.00 and SLBE set-aside; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026; due April 3, 2026) for direct-to-manufacturer prescription programs; and the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. The code itself shows minimal direct recent activity — pursuit under this code should focus on adjacent pharmaceutical and medical supply procurement where sulfamethoxypyridazine may be included as a line item within larger generic or OTC product awards.